Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice

References

• Uemura M, Swenson ES, Gaça MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell 2005; 16: 4214–24
   PubMed Web of Science ®Google Scholar
• Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumor necrosis factor α signaling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415–24
   PubMed Web of Science ®Google Scholar
• Friedman SL. Molecular regulation of hepatic fibrosis: an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247–50
   PubMed Web of Science ®Google Scholar
• Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47: 699–710
   PubMed Web of Science ®Google Scholar
• Hazra S, Miyahara T, Rippe RA, Tsukamoto H. PPAR gamma and hepatic stellate cells. Comp Hepatol 2004; 3 Suppl 1: S7
   Google Scholar
• Nan Y, Wu W, Yao X, Wang L. The role of apoptosis and the related genes in non-alcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi 2007; 15: 41–6
   PubMedGoogle Scholar
• Fatty liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases. Zhanghua Ganzangbing Zazhi 2006;14:161–3.
   Google Scholar
• Chinese Society of Infectious Diseases Study and Parasitology and Chinese Society of Hepatology of Chinese Medical Association. The programme of prevention and cure for viral hepatitis. Zhonghua Neike Zazhi 2001;40:62–8.
   Google Scholar
• Yu J, Ip E, Dela Pena A, Hou JY, Sesha J, Pera N, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 2006; 43: 826–36
   PubMed Web of Science ®Google Scholar
• Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067–75
   PubMed Web of Science ®Google Scholar
• Galli A, Crabb D, Price D, Ceni E, Salzano R, Surrenti C, et al. Peroxisome proliferator activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology 2000; 31: 101–8
   PubMed Web of Science ®Google Scholar
• Tahan V, Eren F, Avsar E, Yavuz D, Yuksel M, Emekli E, et al. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci 2007; 52: 3465–72
   PubMed Web of Science ®Google Scholar
• Aithal GP Thomas JA Kaye PV Lawson A Ryder SD Spendlove I , et al Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008 Jun 25. [Epub ahead of print].
   Google Scholar
• Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100–10
   PubMed Web of Science ®Google Scholar
• Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, et al. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 2003; 52: 1311–18
   PubMed Web of Science ®Google Scholar
• Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168–81
   PubMed Web of Science ®Google Scholar
• He W, Barak Y, Hevener A, Olson P, Liao D, Le J, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003; 100: 15712–7
   PubMed Web of Science ®Google Scholar
• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–112
   PubMed Web of Science ®Google Scholar
• Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. J Gastrointest Liver Dis 2006; 15: 363–73
   PubMedGoogle Scholar
• Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis?. Eur J Gastroenterol Hepatol 2004; 16: 123–6
   PubMed Web of Science ®Google Scholar
• Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, et al. Inhibition of TGF-β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005; 145: 166–77
   PubMed Web of Science ®Google Scholar
• Gooch JL, Gorin Y, Zhang B-X, Abboud HE. Involvement of calcineurin in transforming growth factor-β-mediated regulation of extracellular matrix accumulation. J Biol Chem 2004; 279: 15561–70
   PubMed Web of Science ®Google Scholar
• Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin 1, tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1995; 95: 1669–75
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209–18
   PubMed Web of Science ®Google Scholar
• Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Ann Rev Pharmacol Toxicol 2005; 45: 605–28
   PubMed Web of Science ®Google Scholar
• Chen YW, Wu JX, Chen YW, Li DG, Lu HM. Tetrandrine inhibits activation of rat hepatic stellate cells in vitro via transforming growth factor-beta signaling. World J Gastroenterol 2005; 11: 2922–6
   PubMed Web of Science ®Google Scholar
• Weng HL, Ciuclan L, Liu Y, Hamzavi J, Godoy P, Gaitantzi H, et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 2007; 46: 1257–70
   PubMed Web of Science ®Google Scholar
• George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Therapy 2007; 14: 790–803
   PubMed Web of Science ®Google Scholar
• Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399–410
   PubMed Web of Science ®Google Scholar
• Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762–71
   PubMed Web of Science ®Google Scholar
• Tang M, Potter JJ, Mezey E. Leptin enhances the effect of transforming growth factor beta in increasing type I collagen formation. Biochem Biophys Res Commun 2002; 297: 906–11
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816–27
   PubMed Web of Science ®Google Scholar
• Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001; 34: 859–67
   PubMed Web of Science ®Google Scholar